TRAVERE THERAPEUTICS, INC. Research and Development Expense
TRAVERE THERAPEUTICS, INC. (TVTX) reported Research and Development Expense of $7.50 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-07
- TRAVERE THERAPEUTICS, INC. research and development expense for the quarter ending 2023-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. research and development expense for the quarter ending 2023-06-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. research and development expense for the quarter ending 2023-03-31 was $7.50M.
- TRAVERE THERAPEUTICS, INC. research and development expense for the quarter ending 2021-09-30 was $48.41M, a 49.64% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. research and development expense for fiscal 2022 was $7.50M.
- TRAVERE THERAPEUTICS, INC. research and development expense for fiscal 2019 was $140.96M, a 13.90% increase from fiscal 2018.
- TRAVERE THERAPEUTICS, INC. research and development expense for fiscal 2018 was $123.76M, a 58.32% increase from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. research and development expense for fiscal 2017 was $78.17M, a 10.37% increase from fiscal 2016.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 10 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 22 month | Research and Development Expense 25 month | Research and Development Expense 28 month | Research and Development Expense 31 month | Research and Development Expense 34 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $7.50M 10-Q · filed 2023-11-07 | |||||||||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.50M 10-Q · filed 2023-08-03 | ||||||||||||
| 2023-03-31 | $7.50M 10-Q · filed 2023-05-04 | |||||||||||||
| 2022-12-31 | $7.50M 10-K · filed 2023-02-23 | |||||||||||||
| 2021-09-30 | $48.41M 10-Q · filed 2021-10-29 | $100.21M derived: sum of 2 quarters · filed 2021-10-29 | $148.16M 10-Q · filed 2021-10-29 | |||||||||||
| 2021-06-30 | $51.81M 10-Q · filed 2021-07-29 | $99.75M 10-Q · filed 2021-07-29 | ||||||||||||
| 2021-03-31 | $47.95M 10-Q · filed 2021-05-06 | |||||||||||||
| 2020-09-30 | $32.35M 10-Q · filed 2021-10-29 | $63.14M derived: sum of 2 quarters · filed 2021-10-29 | $93.39M 10-Q · filed 2021-10-29 | $129.75M derived: sum of 4 quarters · filed 2021-10-29 | ||||||||||
| 2020-06-30 | $30.79M 10-Q · filed 2021-07-29 | $61.04M 10-Q · filed 2021-07-29 | $97.41M derived: sum of 3 quarters · filed 2021-07-29 | $130.63M derived: sum of 4 quarters · filed 2021-07-29 | ||||||||||
| 2020-03-31 | $30.25M 10-Q · filed 2021-05-06 | $66.61M derived: sum of 2 quarters · filed 2021-05-06 | $99.83M derived: sum of 3 quarters · filed 2021-05-06 | $137.77M derived: sum of 4 quarters · filed 2021-05-06 | ||||||||||
| 2019-12-31 | $36.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $69.59M derived: sum of 2 quarters · filed 2020-11-05 | $107.52M derived: sum of 3 quarters · filed 2020-11-05 | $140.96M 10-K · filed 2020-02-24 | ||||||||||
| 2019-09-30 | $33.22M 10-Q · filed 2020-11-05 | $71.15M derived: sum of 2 quarters · filed 2020-11-05 | $104.60M 10-Q · filed 2020-11-05 | $136.81M derived: sum of 4 quarters · filed 2020-11-05 | ||||||||||
| 2019-06-30 | $37.93M 10-Q · filed 2020-07-31 | $71.38M 10-Q · filed 2020-07-31 | $103.59M derived: sum of 3 quarters · filed 2020-07-31 | $136.04M derived: sum of 4 quarters · filed 2020-07-31 | ||||||||||
| 2019-03-31 | $33.44M 10-Q · filed 2020-05-11 | $65.66M derived: sum of 2 quarters · filed 2020-05-11 | $98.10M derived: sum of 3 quarters · filed 2020-05-11 | $132.56M derived: sum of 4 quarters · filed 2020-05-11 | ||||||||||
| 2018-12-31 | $32.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $64.66M derived: sum of 2 quarters · filed 2020-02-24 | $99.12M derived: sum of 3 quarters · filed 2020-02-24 | $123.76M 10-K · filed 2020-02-24 | ||||||||||
| 2018-09-30 | $32.45M 10-Q · filed 2019-10-30 | $66.91M derived: sum of 2 quarters · filed 2019-10-30 | $91.54M 10-Q · filed 2019-10-30 | $91.76M 10-Q · filed 2018-11-01 | $111.12M derived: sum of 4 quarters · filed 2020-02-24 | |||||||||
| 2018-06-30 | $34.46M 10-Q · filed 2019-08-06 | $59.10M 10-Q · filed 2019-08-06 | $78.67M derived: sum of 3 quarters · filed 2020-02-24 | $98.28M derived: sum of 4 quarters · filed 2020-02-24 | ||||||||||
| 2018-03-31 | $24.64M 10-Q · filed 2019-05-07 | $44.21M derived: sum of 2 quarters · filed 2020-02-24 | $63.82M derived: sum of 3 quarters · filed 2020-02-24 | $83.30M derived: sum of 4 quarters · filed 2020-02-24 | ||||||||||
| 2017-12-31 | $19.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $39.19M derived: sum of 2 quarters · filed 2020-02-24 | $58.67M derived: sum of 3 quarters · filed 2020-02-24 | $78.17M 10-K · filed 2020-02-24 | ||||||||||
| 2017-09-30 | $19.61M 10-Q · filed 2018-11-01 | $39.09M derived: sum of 2 quarters · filed 2018-11-01 | $58.59M 10-Q · filed 2018-11-01 | $80.02M derived: sum of 4 quarters · filed 2019-02-26 | ||||||||||
| 2017-06-30 | $19.48M 10-Q · filed 2018-08-03 | $40.34M 10-Q · filed 2018-08-03 | $60.41M derived: sum of 3 quarters · filed 2019-02-26 | $78.82M derived: sum of 4 quarters · filed 2019-02-26 | ||||||||||
| 2017-03-31 | $20.86M 10-Q · filed 2018-07-06 | $40.92M derived: sum of 2 quarters · filed 2019-02-26 | $59.34M derived: sum of 3 quarters · filed 2019-02-26 | $77.01M derived: sum of 4 quarters · filed 2019-02-26 | ||||||||||
| 2016-12-31 | $20.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $38.48M derived: sum of 2 quarters · filed 2019-02-26 | $56.15M derived: sum of 3 quarters · filed 2019-02-26 | $70.82M 10-K · filed 2019-02-26 | $70.85M 10-K · filed 2017-03-01 | |||||||||
| 2016-09-30 | $18.41M 10-Q · filed 2017-11-07 | $18.43M 10-Q · filed 2016-11-04 | $36.09M derived: sum of 2 quarters · filed 2017-11-07 | $50.76M 10-Q · filed 2017-11-07 | $50.77M 10-Q · filed 2016-11-04 | $66.21M derived: sum of 4 quarters · filed 2018-07-06 | ||||||||
| 2016-06-30 | $17.68M 10-Q · filed 2017-08-09 | $32.35M 10-Q · filed 2017-08-09 | $47.80M derived: sum of 3 quarters · filed 2018-07-06 | $61.86M derived: sum of 4 quarters · filed 2018-07-06 | ||||||||||
| 2016-03-31 | $14.67M 10-Q · filed 2017-05-05 | $30.12M derived: sum of 2 quarters · filed 2018-07-06 | $44.19M derived: sum of 3 quarters · filed 2018-07-06 | $54.75M derived: sum of 4 quarters · filed 2018-07-06 | ||||||||||
| 2015-12-31 | $15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $29.52M derived: sum of 2 quarters · filed 2018-07-06 | $40.08M derived: sum of 3 quarters · filed 2018-07-06 | $50.43M 10-K · filed 2018-07-06 | ||||||||||
| 2015-09-30 | $14.06M 10-Q · filed 2016-11-04 | $24.63M derived: sum of 2 quarters · filed 2016-11-04 | $34.97M 10-Q · filed 2016-11-04 | $49.87M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||||
| 2015-06-30 | $10.56M 10-Q · filed 2016-08-05 | $20.91M 10-Q · filed 2016-08-05 | $35.81M derived: sum of 3 quarters · filed 2017-03-01 | $48.45M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||||
| 2015-03-31 | $10.35M 10-Q · filed 2016-05-05 | $10.35M 10-Q · filed 2015-05-11 | $25.24M derived: sum of 2 quarters · filed 2017-03-01 | $37.89M derived: sum of 3 quarters · filed 2017-03-01 | $51.20M derived: sum of 4 quarters · filed 2017-03-01 | |||||||||
| 2014-12-31 | $14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $27.54M derived: sum of 2 quarters · filed 2017-03-01 | $40.85M derived: sum of 3 quarters · filed 2017-03-01 | $47.80M 10-K · filed 2017-03-01 | $47.80M 10-K · filed 2015-03-11 | |||||||||
| 2014-09-30 | $12.65M 10-Q · filed 2015-11-06 | $13.02M 10-Q · filed 2014-11-13 | $25.96M derived: sum of 2 quarters · filed 2015-11-06 | $32.90M 10-Q · filed 2015-11-06 | $33.60M 10-Q · filed 2014-11-13 | $37.87M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-06-30 | $13.31M 10-Q · filed 2015-08-10 | $13.70M 10-Q · filed 2014-08-14 | $20.25M 10-Q · filed 2015-08-10 | $20.58M 10-Q · filed 2014-08-14 | $25.22M derived: sum of 3 quarters · filed 2016-02-26 | $26.62M derived: sum of 4 quarters · filed 2016-02-26 | ||||||||
| 2014-03-31 | $6.94M 10-Q · filed 2015-05-11 | $6.89M 10-Q · filed 2014-05-15 | $11.91M derived: sum of 2 quarters · filed 2016-02-26 | $13.31M derived: sum of 3 quarters · filed 2016-02-26 | $13.92M derived: sum of 4 quarters · filed 2016-02-26 | |||||||||
| 2013-12-31 | $4.97M derived: 10-K 12 month − 10-Q/A 9 month · filed 2016-02-26 | $6.37M derived: sum of 2 quarters · filed 2016-02-26 | $6.98M derived: sum of 3 quarters · filed 2016-02-26 | $7.08M 10-K · filed 2016-02-26 | $7.08M 10-K · filed 2014-03-28 | $7.98M 10-K/A · filed 2015-07-09 | ||||||||
| 2013-09-30 | $1.40M 10-Q/A · filed 2015-07-09 | $2.01M derived: sum of 2 quarters · filed 2015-07-09 | $2.11M 10-Q/A · filed 2015-07-09 | $2.54M derived: sum of 4 quarters · filed 2015-07-09 | $3.01M 10-Q/A · filed 2015-07-09 | |||||||||
| 2013-06-30 | $605.20K 10-Q · filed 2014-08-14 | $713.94K 10-Q · filed 2014-08-14 | $1.14M derived: sum of 3 quarters · filed 2015-07-09 | $1.25M derived: sum of 4 quarters · filed 2015-07-09 | $1.61M 10-Q · filed 2013-09-16 | |||||||||
| 2013-03-31 | $158.69K 10-Q · filed 2014-05-15 | $108.73K 10-Q · filed 2013-07-24 | $534.30K derived: sum of 2 quarters · filed 2015-07-09 | $644.96K derived: sum of 3 quarters · filed 2015-07-09 | $786.92K derived: sum of 4 quarters · filed 2015-07-09 | $1.00M 10-Q/A · filed 2013-09-16 | ||||||||
| 2012-12-31 | $375.61K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $486.27K derived: sum of 2 quarters · filed 2015-07-09 | $628.23K derived: sum of 3 quarters · filed 2015-07-09 | $662.50K 10-K/A · filed 2015-07-09 | $524.00K 10-K · filed 2013-06-13 | $877.00K 10-K/A · filed 2013-09-16 | ||||||||
| 2012-09-30 | $110.66K 10-Q/A · filed 2015-07-09 | $252.62K derived: sum of 2 quarters · filed 2015-07-09 | $286.89K 10-Q/A · filed 2015-07-09 | |||||||||||
| 2012-06-30 | $141.96K 10-Q · filed 2013-09-16 | $176.23K 10-Q · filed 2013-09-16 | ||||||||||||
| 2012-03-31 | $34.27K 10-Q/A · filed 2013-09-16 | |||||||||||||
| 2011-12-31 | $353.00K 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |